Smith Stan 4

What Happened

• Stan Smith, a director of MAIA Biotechnology, was granted a derivative award on 2026-06-30: options covering 32,003 shares. The Form 4 reports an acquisition price of $0 and a total reported value of $0 for the award.

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (appears timely).
• Transaction type: Award/Grant of stock options (derivative), reported as A.
• Shares involved: options for 32,003 shares.
• Reported price/value: $0.00 per share; total reported acquisition value $0.
• Vesting/exercise: Per footnote, the options vest 100% on the grant date and are exercisable immediately.
• Beneficial ownership: The securities are beneficially owned through "The Stan V. Smith Trust Dated 1993" (footnote).
• Exercise price or other economic terms beyond immediate vesting are not specified in the provided filing.

Context

• This filing reflects a stock option grant (an award), not an open-market purchase or sale. Although the reported acquisition value is $0, the grant gives the holder the right to buy shares under the option terms; any future exercise, sale, or tax-withholding actions would be reported separately.